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We recently reported the identification of a mouse 
cDNA encoding a new p53-associating protein that 
w e called Mdmx because of its structural sim ilarity  
to Mdm2, a well-known p53“binding protein. Here we 
report the isolation of a cDNA encoding the human 
homolog of Mdmx. The ORF of the cDNA encodes a 
protein of 490 amino acids, 90% similar to mouse 
Mdmx. The homology between Mdmx and Mdm2 is 
m ost prom inent in the p53-binding domain and the 
putative metal-binding domains. The Mdmx protein, 
which, based on SDS-PAGE, has a MW of 80 kDa, can 
bind p53 in vitro. The human MDMX gene is tran­
scribed in all tissues tested, with high levels in thy­
mus. By fluorescence in situ hybridisation analysis 
we mapped the mouse mdmx gene to chromosome 1 
(region F-G ) and the human MDMX gene to chromo-
some lq32. © 1997 Academic Press
INTRODUCTION
The loss of wild-type p53 in human malignancies re­
sults in aberrant cell-cycle progression, escape from 
apoptosis, and enhanced angiogenesis, which all con­
tribute to tumor growth. These biological processes are 
most likely controlled by p53 through its transcription- 
regulating function, which, in human tumors, is usu­
ally altered due to gene mutations (Hollstein et al 
1991, 1994), but can also take place via cytoplasmic 
retention (Moll et al., 1992, 1995) and by association 
with other proteins. Tumor antigens of several DNA 
tumor viruses have been shown to inactivate the func- 
tion(s) of p53, by a tight association (SV40-LT, adenovi­
rus type 5 large E1B protein, HBV X-antigen; Lane 
and Crawford, 1979; Linzer and Levine, 1979; Samow 
etal., 1982; Zantemaei a l ,  1985; Feitelsonei a l ,  1993),
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by enhanced degradation of the p53 protein (HPV-E6; 
Scheffner et a l , 1990; Werness et a l ,  1990), or by as 
yet unknown ways, possibly involving altered oligomer­
ization of p53 (adenovirus type 12 large E1B, adenovi­
rus type 5 E l A; Steegenga et a l ,  1995, 1996). Impor­
tantly, HPV and HBV have been implicated in human 
cervical carcinoma and liver carcinoma (Srivastava et 
al,  1992; Ueda et al., 1995), respectively. In addition, 
some cellular proteins have been found to bind to p53 
and influence its properties as a transcription factor. 
First, the Wilms’ tumor protein WT1, a transcription 
factor itself, is able to modulate p53-regulated tran­
scription (Maheswaran et al, 1993). Recently, the E2F1 
and DPI proteins were also shown to interact directly 
with p53 and inhibit its transcription-stimulation func­
tion (O’Connor et al, 1995; Martin et a l ,  1995). Last, 
p53 was found to complex with the Mdm2 protein 
(Barak and Oren, 1992; Momand et a l ,  1992). The asso­
ciation of Mdm2 with p53 completely abrogates all 
transcription-regulating properties of p53 (Momand et 
al., 1992; Chen et a l ,  1995). Mdm2 most likely func­
tions by concealing the transactivation domain of p53 
(Oliner et al, 1993). Most interestingly, overexpression 
of Mdm2 has been found in a variety of tumors, in 
general correlating with the absence of mutations in 
the p53 gene (Oliner et a l , 1992; Reifenberger et a l ,  
1993; Habuchi et al, 1994; Lianes et a l ,  1994; Corvi 
et a l ,  1995). Overexpression of Mdm2 is apparently 
sufficient for inhibition of the p53 tumor-suppression 
function. Thus, inactivation of p53 in human tumors 
can be achieved by mutation, cytoplasmic retention, or 
overexpression of Mdm2, or by several viral proteins.
We recently reported the identification of a new p53- 
associating protein. The translation product of this 
gene, named mdmx, shows significant homology with 
the Mdm2 protein, especially in the p53-binding do­
main and in the putative functional domains, located 
in the C-terminal part of the protein. We reported that 
the murine Mdmx protein binds to p53 in vivo and, like 
Mdm2, inhibits the activation of transcription by p53 
(Shvarts et a l ,  1996). Unlike mdm2, which is a p53-
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responsive gene, mdmx transcription appears not to be 
regulated in a p53-dependent manner, at least not after 
UV irradiation. This might suggest that mdmx  is not 
a modifier of p53 after UV irradiation. We now report 
the isolation of a human cDNA of 2216 bp that encodes 
the human Mdmx protein of 490 aa. The mouse and 
human Mdmx proteins have 90% identity at the protein 
level. We show that the human Mdmx protein binds to 
p53 in vitro. By FISH analysis we mapped the mouse 
mdmx gene to chromosome 1 region F -G  and its hu­
man homolog to chromosome lq32. We report the iden­
tification of a new member of the mdm  family that 
might be involved in human carcinogenesis.
MATERIALS AND METHODS
Northern analysis. A hum an multi tissue Northern blot (Clon- 
tech) was hybridized with a2P-labeled probes according to the  m anu­
facturer’s manual.
Isolation and sequencing of hum an M DM X cDNA. A cDNA li­
brary from the colonic epithelial cell line T84 in a UNI-Zap-XR vector 
(Stratagene) was screened with mouse m dm x  cDNA probe according 
to the protocol supplied by the manufacturer. pBSK plasmids con­
taining the hum an M DM X  cDNA were obtained w ith R408 helper 
phage (Stratagene).
Double-stranded DNA was sequenced by a T7 polymerase sequenc­
ing kit and AutoRead Sequencing k it (Pharmacia), The sequence 
reactions were subsequently analyzed manually on polyacrylamide 
gel and by the ALF (automatic laser fluorescence) DNA sequencing 
machine (Pharmacia). All the sequence primers were obtained from 
Isogene Bio-Science B.V.
Isolation o f  genomic m dm x DNA clones. To obtain genomic mouse 
mdmx sequences, we screened a genomic mouse library derived from 
129/OLA mice in EMBL3A phage using the standard  procedure 
(Sambrook et a l,  1989). Subclones were generated by digestion with 
Sail and by cloning the fragments into £>a£I-digested pIC20R vector, 
To obtain hum an M D M X  genomic sequences, library NO. 700 (PI 
human), ligated into pAdlOSacBII (Francis et al., 1994), was 
screened with a fragm ent of approximately 560 bp obtained by RT- 
PCR on mRNA isolated from the hum an tumor cell line G401 (Weis- 
mann et al., 1987) with a primer set corresponding to n t  460-478/ 
1003-1022. The presence of MDMXT-specific sequences in  the  geno­
mic clones was established by Southern blot analysis w ith the  use 
of specific cDNA probes (data not shown).
In vitro associations between M dm x and p53 . To obtain in vitro 
translated Mdmx proteins, the full-length coding regions of mouse 
and hum an Mdmx were cloned into pcDNA3 vector (Invitrogen). H u­
man p53 protein was translated in uiti'o from the modified pET 15b/ 
p53 vector (Shvarts et ah, 1996) and the human cJun protein from 
a pBAT vector (Annweiler et al., 1991) containing the hum an cJun 
coding region (pBAT-cJun, a gift from Dr. P. Angel, K arlsruhe, Ger­
many).
In vitro transcription/translation was performed with the use of 
the coupled transcription/translation system obtained from Promega 
(Madison, WI) in the presence of [3BS]methionine. In  vitro translated  
Mdmx proteins were incubated in the presence or absence of bacteri- 
ally produced p53 proteins (Shvarts et al.} 1996) for 30 min on ice. 
Subsequent immunoprécipitations were performed as described pre­
viously (Steegenga et al.} 1995) with a mixture of the monoclonal 
antibodies PAbl22/PAb421 directed against p53, the polyclonal rab­
bit antiserum  pAblOO directed against a peptide of mouse Mdmx, 
or the polyclonal rabbit antiserum pAb55 raised against full-length 
human Mdmx.
To obtain G ST -hum an Mdmx fusion protein, the total coding re­
gion of hum an Mdmx was cloned into vector pRP259, a modified 
pGEX expression vector (Smith and Johnson, 1988), Approximately 
1 fig  of GST-M dm x, bound to beads, was tumbled for 4 h a t 4°C
with labeled in vitro translated p53. Subsequently the beads were 
washed three times with binding buffer. Immunoprecipitated and 
GST-Mdmx-bound proteins were separated on a 9% SDS-polyacryl- 
amide gel, prepared for fluorography with 22.5% PPO (2,5- dipheny- 
loxazole) in dimethylsulfoxide, dried, and exposed to Kodak XAR-5 
film a t -80°C,
Fluorescence in situ hybridization (FISH). FISH  was performed 
on mouse cells regenerated from a muscle biopt and on hum an lym­
phocytes. M etaphase spreads were prepared via the standard proce­
dures. A total of 400 and 150 ng labeled m dm x  probe for mouse and 
hum an chromosomes, respectively, and 5Ox mouse Cot I and 5Ox 
hum an Cot I DNA (Gibco, Life Technology) was dissolved in 12 //I of 
a hybridization solution (50% v/v deionized form amide, 10% dextran 
sulfate, 2x SSC, 1% v/v Tween 20, pH 7.0). Prior to hybridization, 
the probe was denatured at 80°C for 10 min, chilled on ice, and 
incubated at 37°C for 30 min allowing preannealing. After denatur- 
ation of the slides, probe incubations were carried out under an 20 
x 20 mm coverslip in a moist chamber for 45 h. Immunocy to chemical 
detection of the hybridizing probe was achieved with FITC-conju- 
gated sheep-anti-digoxigenin (Boehringer).
For evaluation of the chromosomal spreads a Zeiss epifluorescence 
microscope equipped with the appropriate filter for visualization of DAPI 
and FITC fluorescence was used. Digital images were acquired with a 
high-performance cooled CCD camera (Photometries, Tucson) and fur­
ther processed on a computer with the help of the BDS-Image FISH 
software package (Biological Detection Systems Inc, Rockville, MD).
RESULTS
Molecular Cloning of mdmx cDNA
To identify the human MDMX  cDNA we screened 
a cDNA library from the colonic tumorigenic cell line
Construction of human MDMX cDNA
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FIG . 1- Schematic representation of hum an M D M X  cDNA clones 
obtained from a LambdaZap cDNA library from colon carcinoma cell 
line T84. The Xmn I site in the middle of the cDNA has been used 
to obtain the hum an M D M X  cDNA containing the  complete open 
reading frame.
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CGGCACGAGCTAGGATCTGTGACTGCCACCCCTCCCCCCACCCGGGCTCGGCGGGGGAGC
GACTCATGGAGCTGCCGTAAGTTTTACCAACAGACTGCAGTTTCTTCACTACCAAAATGA
M T
CATCATTTTCCACCTCTGCTCAGTGTTCAACATCTGACAGTGCTTGCAGGATCTCTCCTG 
S F S T S A Q C S T S D S A C R I S P G
G AC AAAT C AAT C AGG T ACG A C C AAAAC TG C CG C T TT TGAAGATTTTG CATG C AG C AGGTG 
Q X N Q V R  P K L P L L K I L H A A G A
CGCAAGGTGAAATGTTCACTGTTAAAGAGGTCATGCACTATTTAGGTCAGTACATAATGG 
Q G E M F T V K E V M H Y L G Q Y  I M V
TGAAGCAACTTTATGATCAGCAGGAGCAGCATATGGTATATTGTGGTGGAGATCTTTTGG 
K Q  L Y D Q Q E Q H M V Y C G G D L L G
GAGAACTACTGGGACGTCAGAGCTTCTCCGTAAAGAACCCAAGCCCTCTCTATGATATGC 
E L  L G R Q S F S V K N P S P L Y D M L
TAAGAAAGAATCTTGTCACTTTAGCCACTGCTACTACAGATGCTGCTCAGACTCTCGCTC 
R K N  L V T  L A T A T T D A A Q T L A L
TCGCACAGGATCACAGTATGGATATTCCAAGTCAAGACCAACTGAAGCAAAGTGCAGAGG 
A Q  D H S M D I P S Q D Q L K Q S A E E
AAAGTTCCACTTCCAGAAAAAGAACTACAGAAGACGATATCCCCACACTGCCTACCTCAG 
S S T S R K R T T E D D I P T L P T S E
AG CATAAATGCATACAT T CTAGAGAAG ATGAAGACTTAATTG AAAATT TAGCC CAAGATG 
H K C  I  H S R E D E D L  I E N L A Q D E
AAACATCTAGGCTGGACCTTGGATTTGAGGAGTGGGATGTAGCTGGCCTGCCTTGGTGGT
T S R L D L G F E E W D V A G L P W W F
TTTTAGGAAACTTGAGAAGCAACTATACACCTAGAAGTAATGGCTCAACTGATTTACAGA
L G N L R S N Y T P R S N G S T D L Q T
CAAATCAGGATGTGGGTACTGCCATTGTTTCAGATACTACAGATGACTTGTGGTTTTTGA
N Q D V G T A I V S D T T D D L W F L N
ATGAGTCAGTATCAGAGCAGTTAGGTGTTGGAATAAAAGTTGAAGCTGCTGATACTGAAC 
E S V S E  Q L G V G I  K V E A A D T E Q
AAA C AAG TGAAGAAG T AGGG AAAG T AAGT G AC AAAAAGGTG ATTG AAGTGGG AAAAAATG 
T S  E E V G K V S D K K V I E V G K N D
ATGACCTGGAGGACTCTAAGTCCTTAAGTGATGATACCGATGTAGAGGTTACCTCTGAGG 
D L E  D S K S L S D D T D V E V T S E D
ATGAGTGGCAGTGTACTGAATGCAAGAAATTTAACTCTCCAAGCAAGAGGTACTGTTTTC
E W Q C T E C K K F N S P S K R Y C F R
GTTGTTGGGCCTTGAGGAAGGATTGGTATTCAGATTGTTCAAAGTTAACCCATTCTCTCT
C W A L R K D W Y S D C S K L T H S L S
CCACGTCTGATATCACTGCCATACCTGAAAAGGAAAATGAAGGAAATGATGTCCCTGATT 
T S  D I  T A I  P E K E N E G N D V P D C
GTCGAAGAACCATTTCGGCTCCTGTCGTTAGACCTAAAGATGCGTATATAAAGAAAGAAA 
R R T  I  S A P V V R P K D A Y I  K K E N
ACTCCAAACTTTTTGATCCCTGCAACTCAGTGGAATTCTTGGATTTGGCTCACAGTTCTG
S K L  F D  P C N S V E F - L D L A H S S E
AAAG C CAAG AG AC C A TCT CAAG C ATGGG AGAACAGT TAG ATAAC C T TT CTG AAC AG AGAA 
S Q E T I S S M G E Q L D N L S E Q R T
CAGATACAGAAAACATGGAGGATTGCCAGAATCTCTTGAAGCCATGTAGCTTATGTGAGA
D T E N M E D C Q N L L K P C S L C E K
AAAGACCACGAGACGGGAACATTATTCATGGAAGGACGGGCCATCTTGTCACTTGTTTTC 
R P R  D G N  X I  H G R T G H L V T C F H
ACTGTGCCAGAAGACTAAAGAAGGCTGGGGCTTCATGCCCTATTTGCAAGAAAGAGATTC 
C A R R L K K A G A S C P  I C K K E I Q
AGCTGGTTATTAAGGTTTTTATAGCATAATGGTAGTACGAACATAAAAATGCATTTATTC 
L V I K V F I A  
AGTTCACTTACCACATTATTTGAAAATCAATCCTTTATTTAATTTTATTTCCAACCTGTC 
AGAGAATGTTCTTAGGCATCAAAATCCAAGGTAGCTGTAAGAAAAATACTGGAGCTAACA 
ATG AAGAACAGAAGTAAT CTGATTAGT CAAATTATTAAGTG C CATGGATTACTTTATGCA 
GCAGTCAGGTACATAGTTAGGTGAACCCAAAAGAAAAACTCTTGAAAACAAGAGATTTCT 
TCCATGCACATTTACAATATTGAGGTATAATTAACATGATAAAGTGTTTCCTTCTAACGA 
GTTGTAGAAATCTGAGTAACCACCCAAAAAAGCAATAGAATGTTTGTGTCACCCCAAAAC 
ACTCCCTTCTGCCCCTCTTCAGACAGTCCTTCAGCTATTTCATGGCTCTCACCCTAGTTT 
TTTTTTTTTTTTGCACTTTTTTTTTTCCGGGGGTATAGGGGAGGTGTGGGGOGACAGGGT 
CTGTCTTGTTCTGTCTCCCAGGCTGAAGTGCAGTGAGTCAAGATTGAGCCACTGCACTCC
AG CCTGGGTG ACAG CGCGAGACTC CATCTCAGAAAAAAAAAAAAAAAAAAAAAAA
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PIG . 2. Nucleotide and derived am ino acid sequence of hum an MDMX. (A) Nucleotide sequence of M DM X  cDNA and predicted protein 
sequence The putative AUG codon is underlined and boldface; putative alternative translation s ta rt sites are shown in  boldface. Conserved 
cysteines in the putative zinc-iinger and  in  the RING finger domains together with the core amino acids are given in  boldface italics, and 
a putative nuclear localization signal is underlined. (B) Sequence alignment of Mdm-like proteins.
T84 (Stratagene) with a mouse mdmx  cDNA probe 
(see Materials and Methods). Two independent phage 
clones, which remained positive after three rounds 
of purification, were isolated and purified to homoge­
neity. Sequence analysis showed inserts ofl260 and 
2260 bp (clone 1 and clone 2, respectively, in Fig. 1).
The shortest construct shows a strong homology with 
the 5' part of the previously identified mouse mdmx  
cDNA (Shvarts et aL, 1996), including the putative 
translation start site. Sequencing of the longest con­
struct revealed that in the 3' part of the insert a 
stretch of 1143 bp shows a strong similarity with the
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FIG . 2— Continued
3' part of the mouse mdmx  cDNA, including the 
translation stop codon. Clone 1 and clone 2 showed 
a 700-bp identical sequence (Fig. 1). Comparing these 
available sequences with the mouse mdmx  cDNA and 
the human MDM2  cDNA sequence suggested that 
these 700 bp are a real overlap, allowing us to gener­
ate a human M DM X  cDNA with the use of an unique 
X m n l  recognition site present in the 700-bp overlap. 
RT-PCR analysis on mRNAs from normal human 
cells and a human tumor cell line with primers from 
outside the overlapping region yielded a fragment of 
a length expected from the combined cDNA (data not 
shown). The human MDMX  cDNA is at the 3' end, 
approximately 500 bp longer than the thus far identi­
fied mouse mdmx  cDNA because of a longer 3 '-un­
translated region. This 3' UTR is similar to that of 
the human MDM2  cDNA in that it contains an Alu  
repeat as has been described for the MDM2 cDNA. 
This human M DM X  cDNA contains an open reading 
frame of 490 amino acids with strong homology to 
the mouse Mdmx protein sequence (Fig. 2A).
At the moment we do not know for sure the exact 
nature of the 5' part of the cDNA insert of clone 2. 
However, we propose this part to be intron sequences, 
because comparison with the genomic organization of 
the mouse mdm2  gene indicates that the junction be­
tween the unknown 5' sequences and the Mdmx-homol- 
ogy region is exactly at a splice acceptor site (Jones et 
al., 1996; Montes de Oca Luna, 1996). Another explana­
tion for the presence of these sequences is not excluded.
Sequence alignment of human MDMX  with human 
MDM2 revealed, analogous to mouse mdmx,, a signifi­
cant homology at both the DNA and the protein levels. 
Figure 2A shows the cDNA sequence of human MDMX  
and the putative open reading frame, encoding a pro­
tein of 490 aa. The sequence alignment of the Mdm- 
like proteins is shown in Fig. 2B. All proteins share the 
p53-binding site, which is located in their N-terminus
(Chen et al., 1995; Brown et al., 1993; Haines et al., 
1994; Shvarts et al., 1996). The Mdm2 mRNAs contain 
additional AUG codons at positions +50 and -1-62, 
which have been shown to be real alternative transla­
tion start sites in both in vivo and in vitro translation 
assays (Barak et al., 1994; Zauberman et al., 1995), 
These AUGs are also present in the mdmx sequence at 
approximately the same positions (+46, +53, and +61). 
We have no direct evidence that they function as alter­
native starts in the MDMX  mRNA, although in vitro 
translation yields protein products of the expected size, 
but also of a smaller size (see below). It suggests that 
the MDMX  mRNA might give rise to different protein 
products, as has been described for Mdm2. At the C- 
terminus the putative metal-binding domains, residues 
306 to 323 and residues 439 to 479 in the human Mdmx 
protein, are highly conserved between the different 
Mdm family members. The latter domain has recently 
been reported to be structurally related to a zinc-bind­
ing domain called the RING finger (Boddy et al., 1994). 
All Mdm proteins contain a putative nuclear localiza­
tion signal (Figs. 2A and 2B). However, the nuclear
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FIG« 3. Expression of MDMX mRNA in human tissues, (A) 
Northern blot containing poly(A)+-selected mRNA from human tis­
sues was probed with human MDMX cDNA. (B) The same blot was 
probed with human MDM2 cDNA. (C) Human /?-actin cDNA was 
used as control for the amount of mRNA loaded. Positions of molecu- 
lar-weight markers (kb) are indicated.
localization signal of the Mdm2 protein is found at posi­
tions 178 -183 (RKRHK), in the middle part of the pro­
tein, whereas in the human Mdmx protein it is found 
at positions 442-445 (KRPR) in the C-terminal part
Expression of MDMX mRNAs in Human Tissues
To determine the expression pattern of human 
MDMX mRNA we performed Northern blot analysis on 
a human multi tissue blot. Figure 3A shows that a 
10-kb human MDMX transcript is synthesized in all 
tissues, with the highest amount in the thymus and 
a very low expression in colon. An additional shorter 
transcript of approximately 2.2 kb is detectable in tes­
tis. We do not know the exact nature of the different 
mRNAs, but the mRNA expression pattern of the 
mouse and the human is rather conserved and will be 
discussed in more detail later. Furthermore, expression 
of human MDMX mRNA was found in all tissues and 
cell lines tested by RT-PCR (data not shown). We com­
pared the expression of human MDMX with that of 
MDM2 by reprobing the same blot with an MDM2 
probe (Fig. 3B). The human MDM2 gene was pre­
viously shown to be expressed in a 5.5-kb transcript, 
first identified by Oliner et a l  (1992) predominantly in 
skeletal muscle and liver, with somewhat lower levels
in pancreas and lung (Ladanyi et al., 1993). A 5.5-kb 
MDM2 transcript was detected, but we find the MDM2 
gene to be almost equally expressed in all tissues on 
this blot with only a somewhat higher expression in the 
thymus, but certainly not as prominent as the MDMX
transcript.
In Vitro Interaction between Mdmx and p53
We have shown previously that mouse Mdmx can 
bind p53 in vivo (Shvarts et a l , 1996). To investigate 
the in vitro interaction between human and mouse 
Mdmx and human p53, we performed two types of ex­
periments. First, we mixed in vitro translated, 3GS-la- 
beled Mdmx with bacterially produced and purified p53 
protein (see Materials and Methods). After this incuba­
tion immunoprécipitations with anti-p53 and anti- 
Mdmx antibodies were performed.
The results presented in Figs. 4A and 4B demon­
strate that in the presence of p53 protein significant 
amounts of the in vitro translated human and mouse 
Mdmx proteins are coimmunoprecipitated with a mix­
ture of the anti-p53 antibodies PAb 122/PAb 421. Fur­
thermore, it seems that only the upper band of mouse 
Mdmx, which is probably generated from the first in­
frame AUG, interacts with p53, suggesting that the 
protein lacking the N-terminal part does not bind p53. 
Although difficult to see in Fig. 4, the same seems to 
be true for the human Mdmx. To verify the in vitro 
binding association between human Mdmx and p53, a 
GST-Mdmx fusion protein was coupled to glutathione 
beads and incubated with 35S-labeled, in vitro trans­
lated human p53 or cjun as a control. As can be seen in 
Fig* 4C, the GST-Mdmx protein specifically interacts 
with human p53 and not with cJun, while GST alone 
binds neither protein.
We conclude from these results that both human 
and mouse Mdmx proteins associate with p53 protein 
in vitro and that the binding domain is probably lo­
cated in the extreme N-terminal part of the Mdmx 
proteins.
Chromosomal Mapping of the mdmx Genes
Amplification of the human MDM2 gene has been 
observed in a variety of tumors (Oliner et a l , 1992; 
Reifenberger e ta l ,  1993;Habuchie£ a l } 1994; Lianes 
e t a l 3 1994; Corviet a l ,  1995), Since the MDMX  gene 
might be present in amplicons described in human 
tumors, we set out to localize the gene. To begin with, 
the mouse mdmx gene was mapped with FISH to 
chromosome 1, region F-G  (Lyon and Searle, 1989; 
Figs. 5A and 5B). This region is in synteny with a 
region on the long arm of the human chromosome 1. 
This possible location of the human MDMX  gene was 
verified by FISH analysis with the PI clone con­
taining human MDMX sequences. The human 
MDMX gene was mapped to human chromosome 
lq32 (Figs. 5C and 5D), This region was recently re­
ported to be amplified in a subset of liposarcomas
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FIG. 4. In vitro association between Mdmx and p53. (A, B) Immunoprécipitations on a mixture of in vitro translated , 3(5S-labeled Mdmx 
proteins and bacterially produced p53 w ith  a mouse Mdmx-specific polyclonal antibody pAblOO (aMMDMX), a polyclonal antibody recognizing 
human Mdmx pAb55 (aHMDMX), or a m ixture of PAb 122/421 (crp53); nonimmune mouse antibody (N.I. mouse) was used in control 
immunoprécipitations as indicated. (C) GST-HMDMX fusion protein or only GST bound to glutathione beads was mixed with either in 
vitro translated ,r}BS-labeled p53 protein or cJun protein. After th is  incubation the  beads were washed and bound proteins were separated 
on SDS-PAGE.
(Szymanska et ah, 1996; Forus et al., 1995). The pos­
sible amplification of the MDMX  gene in these tu­
mors is currently under investigation.
D IS C U S S IO N
We report here the isolation and identification of the 
human counterpart of the mouse mdmx  gene. The hu­
man MDMX gene encodes a protein of 490 aa that is 
90% homologous to mouse Mdmx (Shvarts et aL, 1996), 
The amino acid sequence predicts a protein with a theo­
retical molecular weight of 54 kDa. However, on SD S- 
PAGE human Mdmx was found to migrate as a protein 
with a molecular weight of approximately 80 kDa. This 
behavior corresponds to the observation that the Mdm2 
protein also runs at a much higher molecular weight 
on SDS-PAGE than expected from its amino acid se­
quence. We expect the Mdmx amino acid sequence to 
be as presented here, since upstream from the putative 
AUG, in-frame stop codons are found. The apparent 
molecular weight of human Mdmx is somewhat larger 
than that earlier found for mouse Mdmx. This might 
be caused by different posttranslational modifications, 
e.g., phosphorylation, which is known to occur on the 
Mdm2 proteins.
A sequence comparison between human MDMX  and 
human MDM2 reveals conservation that is strongest 
in the p53-binding domain located in the N-terminal 
part of both proteins. Furthermore, putative functional 
domains in the C-terminal part of the proteins are 
highly conserved. These domains consist of a zinc finger 
and a zinc-binding domain called the RING finger. The 
latter is thought to be involved in protein-protein in­
teraction (Boddy et ah, 1994).
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Mouse chromosome 1
FIG. 5 . Chromosomal localization of the mdmx genes by fluorescence in situ  hybridization. (A, C) Mapping of the m dm x  gene on mouse 
and hum an metaphase chromosomes, respectively» Probe DNA, light spots; chromosomes are counter stained with DAPI. (B, D) Giemsa- 
like banding to identify the chromosome and localize the probe on mouse chromosome 1 F -G  and on hum an chromosome lq32. At least 
20 informative chromosome spreads were used to determine the localization of the mdmx. genes.
By Northern blot analysis we detect a 10-kb tran­
script of human MDMX in most tissues, with a rela­
tively high expression in thymus, Also mouse thymus 
was found to express relatively high levels of the mu­
rine mdmx mRNAs (data not shown). The murine 
mdmx gene is expressed prominently into two long 
mRNAs of approx. 10 and 7.5 kb in all tested tissues 
and a mRNA of 2.2 kb, which is highly expressed in 
testis and to a very low level in other tissues (Shvarts 
et a/., 1996). An MDMX mRNA of approx. 2.2 kb is also 
found in human testis. This mRNA is not detected in 
the other tissues, but if the expression of this mRNA 
in the other tissues is as low relative to the longer 
mRNA as in mouse tissues, it might be a detection 
problem. Thus, the mRNA expression patterns of the 
human and mouse mdmx genes are rather similar, with 
the possible exception of the shorter mRNAs in tissues 
other than testis. It is not firmly established whether
primed mRNAs. Second, an entry in the NCBI EST 
database of 275 bp (L44283), derived from human thy­
mus RNA, is identical over a stretch of 113 bp with the 
human MDMX cDNA sequence shown here (Fig, 6). 
From studies on the genomic organization of the mouse 
gene we know this to be exon 2. Both 5' and 3' of these 
exon sequences the sequence of the EST diverges from 
the cDNA sequence (Fig. 6), but now shows similarity 
with intron sequences of the mouse mdmx gene (not 
shown). These results already suggested that unspliced 
or not fully spliced mdmx mRNAs are expressed. In 
addition, we performed an RT-PCR assay on mouse 
thymus mRNA with one primer derived from exon 2 
and another from the following intron. A product of 
the expected length could be detected, again suggesting 
that (partly) unspliced mdmx mRNAs are expressed.
The 5' end of cDNA most likely represents the ap­
proximate 5' end of the mRNA, as indicated by 5'-
the mRNAs detected all contain the coding region here RACE experiments (Shvarts et aL, 1996) and because
presented. However, we hypothesize that the longer 
hybridizing RNA band represents not (fully) processed 
mRNA because of the following reasons. First, the
in the mouse genome just upstream of this region pro­
motor activity was found (R.C.A. van Ham and A.G. 
Jochemsen, unpublished results). From these results 
cDNA clone 2 we isolated most likely contains intron we hypothesize that the long mRNAs represent not 
sequences, while the library was made from oligo(dT)- fully processed mRNA and that the cDNA sequence we
hu m d m x  
EST
hu m d m x
EST
1-GGCACGAGCTAGGATCTGTGACTGCCACCCCTCCCCCCACCCGGGCTCGGCGGGGGAGCGACTCATGGAGCTGCCGTAAG 
ATGTGTCATATG TGTGTTTTACTTCTGCTGGTTGCCTTTGTGTGAATGCTAAATAGGGAATTTTCTGCATTAGAATAGATGTTATAAA TTTTTTTTTCTATTTAG
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FIG. 6 . Alignment of the 5 '-part of the human MDMX cDNA sequence with an EST from the NCBI database (Accession No. L44283).
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now show is a representation of the smaller mRNA of 
2.2 kb, although other possibilities cannot be excluded. 
Thus, although we find the human MDMX  10-kb 
mRNA to be highly expressed in thymus, it remains to 
be seen whether this has consequences at the protein 
level. It is not excluded that the unspliced mRNAs also 
code for Mdmx-like proteins, since in clone 2 an in- 
frame ATG codon is present just eight amino acids in 
front of the Mdmx-homology region. It will be interest­
ing to find out whether this relatively high mRNA ex­
pression will turn out to be important in the differentia­
tion of T-cells or be reflected in a role of MDMX  (over)- 
expression in hematological malignancies, as has been 
reported for MDM2 (Bueso-Ramos e ta l ., 1993; Maestro 
et al., 1995; Zhou et aL} 1995). MDM2 amplification is 
found in approximately 30% of human sarcomas 
(Oliner et al., 1992). A recent analysis of liposarcomas 
shows 50% amplification in 12ql4, most probably in­
volving MDM2. In several liposarcomas (4/14) amplifi­
cation around lq32 has also been found, possibly indi­
cating involvement of MDMX  (Szymanska et al., 1996). 
Whether the MDMX  gene is present in this amplicon 
is currently under investigation.
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